CAS Number: 936563-96-1

Stage: Pipeline

Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor used for the treatment of B-cell malignancies, including CLL, MCL, and WM. By targeting B-cell signaling, Ibrutinib disrupts tumor survival and proliferation. It is a major advancement in oral targeted cancer therapies and has transformed treatment paradigms in hematology. Explore Royal Pharma as your potential partner for Ibrutinib API.